Skip links

Main navigation

TEST ICTC REPORT

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Psoriasis Drug: Guselkumab|Drug: Placebo Janssen Research & Development, LLC Phase 3
A Study of LY3074828 in Participants With Moderate to Severe Plaque Psoriasis Plaque Psoriasis Drug: LY3074828|Drug: Placebo Eli Lilly and Company Phase 2
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp Actinic Keratosis Drug: ALA|Drug: Vehicle|Device: IBL 20 mW|Device: IBL 10 mW DUSA Pharmaceuticals, Inc. Phase 3
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis Plaque Psoriasis Drug: 122-0551 Foam|Drug: Vehicle Foam Therapeutics, Inc. Phase 3
Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis Actively Extending Plaque Psoriasis|Moderate to Severe Plaque Psoriasis Drug: IMO-3100|Drug: Saline for Injection|Drug: IMO-3100 Idera Pharmaceuticals, Inc. Phase 2
A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris Acne Vulgaris Drug: adapalene 0.1% and benzoyl peroxide 2.5% topical gel|Drug: EPIDUO|Drug: Placebo (Vehicle Gel) Actavis Mid-Atlantic LLC
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo Rosacea Drug: Doxycycline|Other: Placebo Galderma Laboratories, L.P. Phase 4
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis Psoriasis Drug: GSK2894512 1% Cream|Drug: GSK2894512 0.5% Cream|Drug: Vehicle cream GlaxoSmithKline Phase 2
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis Plaque Psoriasis Drug: IDP-122 Lotion|Drug: IDP-122 Vehicle Lotion Valeant Pharmaceuticals International, Inc. Phase 3
A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis Psoriasis Drug: JNJ-38518168 60 mg|Drug: JNJ-38518168 30 mg|Drug: JNJ-38518168 3 mg|Drug: Placebo Janssen Research & Development, LLC Phase 2
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305) Plaque Psoriasis Drug: 000-0551 Lotion|Drug: Vehicle Lotion Therapeutics, Inc. Phase 3
BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris Acne Vulgaris Drug: BLI1100|Drug: BLI1100 – modified formulation|Drug: Placebo Braintree Laboratories Phase 2
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis Psoriasis Drug: IDP-118 Lotion|Drug: Tazorac Cream|Drug: IDP-118 Vehicle Lotion|Drug: IDP-118 Vehicle Cream Valeant Pharmaceuticals International, Inc. Phase 2
Microneedle Lesion Preparation Prior to ALA-PDT for AK on Face Actinic Keratosis Drug: ALA|Drug: Topical Solution Vehicle|Device: IBL 10 mW|Procedure: Microneedle lesion preparation|Device: IBL 20 mW DUSA Pharmaceuticals, Inc. Phase 2
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients Psoriasis Drug: VTP-43742|Drug: Placebo 1|Drug: Placebo 2 Vitae Pharmaceuticals, Inc. Phase 1|Phase 2
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Androgenetic Alopecia Drug: SM04554|Drug: Vehicle Samumed LLC Phase 2
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel Acne Vulgaris Drug: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug: DUAC® Gel|Drug: Placebo Cadila Healthcare Limited Phase 3
Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK) Actinic Keratosis Drug: Broad Area ALA 1-hour incubation|Drug: Broad Area ALA 2 hour incubation|Drug: broad area ALA 3-hour incubation|Drug: Spot ALA 2 hour incubation|Drug: Vehicle PDT|Device: Blue Light Treatment DUSA Pharmaceuticals, Inc. Phase 2
Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis Psoriasis Drug: IDP-118 Lotion|Drug: HP Monad Lotion|Drug: Ultravate Cream|Drug: Tazorac Cream Valeant Pharmaceuticals International, Inc. Phase 1
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses Actinic Keratosis Drug: GDC 695|Drug: Diclofenac Sodium Gel, 3%|Drug: Vehicle gel Gage Development Company, LLC Phase 3
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris Acne Drug: IDP-121 Lotion|Drug: IDP-121 Vehicle Lotion Valeant Pharmaceuticals International, Inc. Phase 1
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris Acne Vulgaris Drug: Tazarotene Cream 0.1%|Drug: Tazorac®|Drug: Placebo Fougera Pharmaceuticals Inc. Phase 3
A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis Plaque Psoriasis Drug: Tazarotene Cream 0.05%|Drug: TAZORAC® (tazarotene) Cream 0.05%|Drug: Placebo Fougera Pharmaceuticals Inc. Phase 3
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis Atopic Dermatitis Drug: PF-04965842|Drug: PF-04965842|Drug: PF-04965842|Drug: PF-04965842|Drug: Placebo Pfizer Phase 2
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Psoriasis Drug: ABBV-066|Drug: ustekinumab|Drug: placebo to ABBV-066|Drug: placebo to ustekinumab AbbVie|Boehringer Ingelheim Phase 3
An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris Acne Vulgaris Drug: CB-03-01 cream, 1% Cassiopea SpA Phase 3
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment Psoriasis Drug: ABBV-066|Drug: Placebo AbbVie|Boehringer Ingelheim Phase 3
A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis Actinic Keratosis Drug: Ingenol Mebutate (Picato®)|Drug: Generic Ingenol Mebutate|Drug: Vehicle Foam Actavis Inc. Phase 3
Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis Actinic Keratosis Drug: Carac Cream|Drug: Generic Fluorouracil Cream|Drug: Placebo Actavis Inc. Phase 3
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25) Acne Vulgaris Drug: CB-03-01 cream, 1%|Drug: Vehicle cream Cassiopea SpA Phase 3
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris Acne Vulgaris Drug: BLI1100-1|Drug: BLI1100-2|Drug: BLI1100-3|Drug: Control group|Drug: Placebo Braintree Laboratories Phase 2
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Rosacea Drug: Omiganan|Drug: Vehicle Cutanea Life Sciences, Inc. Phase 3
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel Rosacea Drug: Omiganan Cutanea Life Sciences, Inc. Phase 3
Efficacy and Safety of CD5789 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris Acne Vulgaris Drug: CD5789 50μg/g cream|Drug: Placebo cream Galderma R&D Phase 3
Long-term Safety Study of DRM04 in Subjects With Primary Axillary Hyperhidrosis Hyperhidrosis Drug: DRM04 Topical Wipes Dermira, Inc. Phase 3
Study of DRM04 in Axillary Hyperhydrosis Hyperhidrosis Drug: DRM04 Topical Wipes|Other: Placebo Dermira, Inc. Phase 3
Finasteride Treatment of Severe Nodulocystic Acne NODULOCYSTIC ACNE Drug: Finasteride 23.5 mg tablets|Drug: Finasteride 33.5 mg tablets|Drug: Placebo tablets Elorac, Inc. Phase 2
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis Hyperhidrosis Drug: BBI-4000 Low Concentration|Drug: BBI-4000 Middle Concentration|Drug: BBI-4000 High Concentration|Drug: Placebo Brickell Biotech, Inc. Phase 2
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne Acne Vulgaris Drug: Sarecycline|Drug: Placebo Warner Chilcott Phase 3
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Dermatitis, Atopic Drug: dupilumab|Drug: placebo Regeneron Pharmaceuticals|Sanofi Phase 3
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD) Atopic Dermatitis Drug: Dupilumab|Drug: placebo Regeneron Pharmaceuticals|Sanofi Phase 2
Twelve Month Follow-Up of CP0108 Actinic Keratosis Drug: Aminolevulinic Acid (ALA)|Drug: Topical Solution Vehicle|Device: BLU-U Blue Light Photodynamic Therapy Illuminator DUSA Pharmaceuticals, Inc. Phase 3
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment Psoriasis Drug: Guselkumab 100 mg|Drug: Placebo for guselkumab|Drug: Adalimumab|Drug: Placebo for adalimumab Janssen Research & Development, LLC Phase 3
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Psoriasis Drug: Guselkumab 100 mg|Drug: Placebo for guselkumab|Drug: Adalimumab|Drug: Placebo for adalimumab Janssen Research & Development, LLC Phase 3
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab Psoriasis Drug: Ustekinumab|Drug: Guselkumab|Drug: Placebo for ustekinumab|Drug: Placebo for guselkumab Janssen Research & Development, LLC Phase 3
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities Actinic Keratosis Drug: Aminolevulinic Acid (ALA)|Drug: Topical Solution Vehicle|Device: Blue Light Photodynamic Therapy Illuminator (BLU-U) DUSA Pharmaceuticals, Inc. Phase 3
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) Plaque Psoriasis Drug: Etanercept|Drug: CHS-0214 Coherus Biosciences, Inc.|Baxalta US Inc. Phase 3
A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea Rosacea Drug: Azelaic acid Actavis Inc. Phase 3
A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses Actinic Keratosis Drug: Imiquimod Actavis Inc. Phase 3
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis Actinic Keratosis Drug: LEO 43204|Drug: Placebo LEO Pharma Phase 1|Phase 2
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira Plaque Type Psoriasis Drug: GP2017 Adalimumab|Drug: Humira ® Adalimumab Sandoz Phase 3
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis Actinic Keratosis Drug: Diclofenac sodium|Other: Placebo Actavis Inc. Phase 3
VPD-737 for Treatment of Chronic Pruritus Chronic Pruritus Drug: VPD-737|Drug: Placebo Menlo Therapeutics Inc. Phase 2
Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis Atopic Dermatitis Drug: Dupilumab (REGN668/SAR231893) Regeneron Pharmaceuticals|Sanofi Phase 3
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis Psoriasis Drug: DFD01 Spray|Drug: Comp01 Lotion|Drug: Vehicle Lotion|Drug: Vehicle Spray Promius Pharma, LLC Phase 3
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis Psoriasis Drug: M518101|Drug: Vehicle Maruho North America Inc. Phase 3
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Moderate to Severe Plaque Psoriasis Drug: 210 mg brodalumab|Drug: 140 mg brodalumab|Drug: ustekinumab|Drug: placebo Amgen Phase 3
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis Actinic Keratosis Drug: Imiquimod Cream, 3.75%|Drug: Zyclara®|Other: Vehicle of Test Product Teva Pharmaceuticals USA Phase 3
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris Acne Vulgaris Drug: CB-03-01|Drug: Vehicle|Drug: CB-03-01 Intrepid Therapeutics, Inc. Phase 2
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC) Basal Cell Carcinoma Genentech, Inc.
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) Psoriasis Drug: 80 mg ixekizumab Dosing Regimen|Drug: 50 mg etanercept|Drug: Placebo Eli Lilly and Company Phase 3
To Evaluate the Safety, Tolerability and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) With Plaque Psoriasis Psoriasis Drug: STF 115469 Foam|Drug: Vehicle Foam GlaxoSmithKline Phase 3
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea Papulopustular Rosacea Drug: Azelaic acid foam, 15% (BAY39-6251)|Drug: Vehicle foam Bayer Phase 3
A Study of Ustekinumab to Evaluate a “Subject-tailored” Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis Psoriasis Drug: Ustekinumab 45 mg|Drug: Ustekinumab 90 mg|Drug: Placebo Janssen Biotech, Inc. Phase 3
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab Psoriasis Drug: Etanercept Amgen Phase 4
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp Actinic Keratosis Procedure: Cryotherapy|Drug: Vehicle|Drug: Ingenol metabute LEO Pharma Phase 3
LEO 90100 in the Treatment of Psoriasis Vulgaris Psoriasis Vulgaris Drug: LEO 90100|Drug: Calcipotriol|Drug: Betamethasone LEO Pharma Phase 2
LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris Psoriasis Vulgaris Drug: LEO 90100|Drug: Betamethasone plus calcipotriol|Drug: Ointment vehicle|Drug: LEO 90100 vehicle LEO Pharma Phase 2
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea Rosacea Drug: Metronidazole Topical Gel 1%|Drug: Metronidazole Topical Gel 1% (Metrogel)|Drug: Placebo Taro Pharmaceuticals USA Phase 1
A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses Actinic Keratoses Drug: imiquimod cream, 3.75%|Drug: Vehicle Cream|Drug: imiquimod cream, 3.75% Actavis Mid-Atlantic LLC
Phase 3 Papulopustular Rosacea Study Papulopustular Rosacea (PPR) Drug: CD5024|Drug: Azelaic acid 15% Gel Galderma Phase 3
BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris Acne Vulgaris Drug: BLI1100|Drug: Vehicle cream Braintree Laboratories Phase 2
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris Acne Vulgaris Drug: Low Strength IDP-107|Drug: High Strength IDP-107|Drug: Placebo Dow Pharmaceutical Sciences Phase 2
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) Psoriasis Vulgaris Drug: Calcipotriol plus betamethasone|Drug: Betamethasone-17,21-dipropionate|Drug: Calcipotriene|Drug: Topical suspension vehicle LEO Pharma Phase 3
Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne Severe Nodular Acne Drug: CIP-Isotretinoin|Drug: Isotretinoin Cipher Pharmaceuticals Inc. Phase 3
A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies Actinic Keratosis Drug: Lesion count Peplin|TKL Research, Inc. Phase 3
A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) Actinic Keratosis Drug: PEP005 (Ingenol Mebutate) gel, 0.015%|Drug: Vehicle Gel Peplin Phase 3
Bioequivalence Study of Two Imiquimod Cream 5% Actinic Keratosis Drug: Imiquimod 5% manufactured by Taro|Drug: Aldara – Imiquimod 5%|Drug: Imiquimod Vehicle manufactured by Taro Taro Pharmaceuticals USA Phase 1
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema Eczema Drug: alitretinoin|Drug: Placebo Stiefel, a GSK Company|Basilea Pharmaceutica|GlaxoSmithKline Phase 3
Chronic Plaque Psoriasis (Ps) Registry Chronic Plaque Psoriasis AbbVie (prior sponsor, Abbott)|AbbVie
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Actinic Keratoses Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel Peplin Phase 3
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis Moderate to Severe Plaque Psoriasis Biological: ABT-874|Biological: etanercept|Drug: placebo AbbVie (prior sponsor, Abbott)|Paragon Biomedical|AbbVie Phase 3
Open Label Continuation Study in Moderate to Severe Psoriasis Moderate to Severe Plaque Psoriasis Drug: ABT-874 AbbVie (prior sponsor, Abbott)|AbbVie Phase 3
Psoriasis Longitudinal Assessment and Registry (PSOLAR) Psoriasis|Arthritis, Psoriatic Biological: ustekinumab|Biological: Biological therapies other than infliximab and ustekinumab|Drug: conventional systemic agents|Biological: infliximab Janssen Scientific Affairs, LLC
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis Atopic Dermatitis LEO Pharma
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) Psoriasis Genentech, Inc. Phase 4